Dr. Jochen Heymanns
Prof. Dr. Rudolf Weide
Dr. Jörg Thomalla
Dr. Christoph van Roye
Dr. Geothy Chakupurakal

Neversstraße 5
56068 Koblenz
Tel.: 0261 30493-0
Fax: 0261 30493-33

Publikationen

Immunoglobulin substitution in patients with indolent non-Hodgkin’s lymphoma
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H.
TumorDiagn u Ther 2016;37:393-397

Follow-up Reality for Breast Cancer Patients – Standardised Survey of Patients and Physicians and Analysis of Treatment Data
Feiten S, Dünnebacke J, Friesenhahn V, Heymanns J, Köppler H, Meister R, Thomalla J, van Roye C, Wey D, Weide R
Geburtshilfe Frauenheilkd 2016; 76(05): 557-563

Adherence assessment of patients with metastatic solid tumors who are treated in an oncology group practice
Feiten S, Weide R, Friesenhahn V, Heymanns J, Kleboth K, Köppler H, van Roye C, Thomalla J
SpringerPlus (2016) 5:270

Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995-2014
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H.
Oncol Res Treat 2016;39:41-44.

Immunoglobulin substitution in patients with indolent non-Hodgkin’s lymphoma
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H.Dtsch Med Wochenschr 2015;140(19):e201-6

NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim – First Interim Analysis
Kurbacher C.M., Fietz T, Diel I, Egert ., Hurtz H-J, Lück A, Weide R, Salat C, Wolff T, Zaiss M, Klare P, Losem C, Illmer T, Weißenborn G, Steffens C, Schulze M, Tesch H, Oskay-Oezcelik G, Teichmann B, Harde J, Scheuerlein R W
Oncol Res Treat 2015;38:221–229

Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive Tumors.
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H
SpringerPlus 2014 3:535.

Breast cancer morbidity – questionnaire survey of patients on the long term effects of disease and adjuvant therapy.
Feiten S, Dünnebacke J, Heymanns J, Köppler H, Thomalla J, van Roye C, Wey D, Weide R
Dtsch Arztebl Int 2014; 111: 537-44.

The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison.
Herth I, Dietrich S, Benner A, Hegenbart U, Rieger M, Stadtherr P, Bondong A, Tran TH, Weide R, Hensel M, Knauf W, Franz-Werner J, Welslau M, Procaccianti M, Görner M, Meissner J, Luft T, Schönland S, Witzens-Harig M, Zenz T, Ho AD, Dreger P
Ann Oncol. 2014;25(1):200-6.

Psychosocial Distress in Caregivers of Patients with a Metastatic Solid Tumor in Routine Care: A Survey in a Community Based Oncology Group Practice in Germany.
Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Köppler H, Mergenthaler U, Thomalla J, van Roye C & Weide R
Cancer and Clinical Oncology 2013,2(2):1-10.

Improved Survival of HER2-Positive Metastatic Breast Cancer in Routine Care
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, Mergenthaler U, van Roye C & Köppler H
Cancer and Clinical Oncology 2013, Vol. 2 (1):17-27

Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C & Köppler H
Leuk Lymphoma. 2013;54(8):1640-6

Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).
Köppler H, Fuss H, Hurtz HJ, Knigge O, Losem C, Reschke D, Schmitz S, Weide R, Weiß J, Hallek M; GCLLSG.
Br J Haematol. 2012;158(2):238-41.

Identifying Caregivers and Their Meaning for Patients with Metastatic Solid Tumours in Routine Care: A Survey at a Community-Based Oncology Group Practice in Germany
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Mergenthaler U, Thomalla J, van Roye C & Köppler H
Cancer and Clinical Oncology. 2012; 1(1): 41-51

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study
Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, Kelaidi C, Pfeilstöcker M, Nösslinger T, Sekeres M, Maciejewski J, Haase D, Schanz J, Seymour J, Kenealy M, Weide R, Lübbert M, Platzbecker U, Valent P, Götze K, Stauder R, Blum S, Kreuzer K-A, Schlenk R, Ganser A, Hofmann W-K, Aul C, Krieger O, Kündgen A, Haas R, Hasford J and Giagounidis A
Leukemia 2012: doi:10.1038/leu.2011.391

Evaluation of psychosocial distress in patients treated in a community-based oncology group practice in Germany
Mergenthaler U, Heymanns J, Köppler H, Thomalla J, van Roye C, Schenk J, Weide R.
Ann Oncol. 2010 Oct 6.

Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.
Weide R, Köppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS.
J Cancer Res Ther.2010 Jan-Mar;6(1):31-5

The impact of new treatment options for advanced colorectal cancer on routine care: Results of a retrospective analysis of 206 consecutive patients treated in a community based oncology group practice
Köppler H, Heymanns J, Thomalla J, Kleboth K, Weide R.
Eur J Cancer Care (Engl). 2009 Oct 14.

Interdisziplinäre ambulante Versorgung
Schmitz S, Heymanns J.
Der Onkologe 2009 Oct;15:1065-1069

Bendamustine/Mitoxantrone/Rituximab (BMR): A short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia (CLL)
Weide R, Mergenthaler U, Friesenhahn V, Kleboth K, Heymanns J, Thomalla J, Köppler H.
Leuk Lymphoma. 2009 Sep;50(9):1468-1474

Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer.
Rhiem K, Wappenschmidt B, Bosse K, Köppler H, Tutt AN, Schmutzler RK.
Clin Oncol (R Coll Radiol). 2009 Aug;21(6):448-50. Epub 2009 Feb 26.

Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Diel IJ, Weide R, Köppler H, Antràs L, Smith M, Green J, Wintfeld N, Neary M, Duh MS.
Support Care Cancer. 2009 Jun;17(6):719-25. Epub 2008 Dec 17.

CT-guided percutaneous core needle biopsy in oncology outpatients: sensitivity, specificity, complications.
Steil S, Zerwas S, Moos G, Bittinger F, Hansen T, Mergenthaler U, Weide R.
Onkologie. 2009 May;32(5):254-8. Epub 2009 Apr 22.

Improved survival of patients with metastatic breast cancer in routine care: results of a retrospective study in a community-based oncology group practice 1995-2005.
Weide R, Mergenthaler U, Pandorf A, Arndt H, Heymanns J, Thomalla J, Köppler H.
Onkologie. 2009 Mar;32(3):107-13. Epub 2009 Feb 13.

Treatment of Advanced Non Small Cell Lung Cancer in Routine Care: A Retrospective Analysis of 212 Consecutive Patients Treated in a Community Based Oncology Group Practice
Koeppler H, Heymanns J, Thomalla J,Kleboth K, Mergenthaler U, Weide R.
Clinical Medicine: Oncology 2009:3 63-70

Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.
Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Bürkle D, Dengler R, Distelrath A, Eckart M, Eckert R, Fries S, Knoblich J, Köchling G, Laubenstein HP, Petrides P, Planker M, Pihusch R, Weide R, Kern W, Haferlach T.
Haematologica. 2009 Jan;94(1):141-4. Epub 2008 Nov 23.

Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma.
Weide R.
Ther Clin Risk Manag. 2008 Aug;4(4):727-32.

Ovarian cancer treatment reality in northern Rheinland-Pfalz (Germany). Suboptimal surgical treatment as a possible cause for inferior survival.
Weide R, Arndt M, Pandorf A, Heymanns J, Thomalla J, Köppler H.
Onkologie. 2007 Dec;30(12):611-7.

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R, Hess G, Köppler H, Heymanns J, Thomalla J, Aldaoud A, Losem C, Schmitz S, Haak U, Huber C, Unterhalt M, Hiddemann W, Dreyling M; German Low Grade Lymphoma Study Group.
Leuk Lymphoma. 2007 Jul;48(7):1299-306.